Maine's medical cannabis caregiver program has functioned for twenty-six years without mandatory seed-to-sale tracking software, and by nearly every measurable outcome, it works. As of 2025, it supports 112,547 registered patients - roughly 8% of the state's population - along with 1,539 caregivers and over 5,000 employees. Annual medical sales still outpace adult-use. The program is, in the language of regulated markets, a success. What's now under pressure is the question of whether that success will be allowed to continue on its own terms.
A Program Built on Agricultural Logic, Not Software Architecture
Maine's medical program was never designed to run like a corporate compliance department. It was designed to run like a farm - because, in most meaningful respects, that's what it is. Caregivers operate under a trip-ticket and transaction-log framework: date, time, location, registration numbers, and product description recorded for every transfer. Facilities and records are subject to inspection. Testing is required only to substantiate claims made on labeling. The state retains statutory authority to audit-test at any time.
That framework produced something rare in legal cannabis: a functioning small-business ecosystem. The smallest registration category allows cultivation of six plants - the lowest barrier to entry in any legal program in the country. The largest caregiver canopy caps at 500 square feet. Mark Barnett, founder and policy director of the Maine Craft Cannabis Association, puts it plainly: "We have by far the highest quality regulatory environment for our medical cannabis program, as evidenced by the amazing number of participants, business participants in that program who are two hundred and fifty thousand dollars a year or less in total turnover."
The Office of Cannabis Policy's own 2025 annual report noted that administrative actions affected just 1% of all registered caregivers, and that most violations were resolved through technical assistance - not fines, not revocations. In agricultural regulatory terms, that is not a "wild, wild West." That is a well-calibrated program.
Lizzy Hayes grows entirely outdoors, off-grid. Her farm holds Clean Cannabis Certification from the Maine Organic Farmers and Gardeners Association, verified against USDA organic handling standards - including audited seed-to-sale records. She sells directly to patients who know her name. Her operation is, by any reasonable definition, exactly what the legalization movement said craft cannabis could look like.
The METRC Question and Where It Comes From
Here's the catch: the compliance infrastructure being pushed toward the medical program comes with a price tag - and a history worth examining.
When Maine voters approved recreational cannabis in 2016 by a narrow 51% margin, the state contracted a consulting group to draft the adult-use framework. That group included Andrew Freedman, Colorado's first cannabis policy director; Lewis Koski, former director of Colorado's Marijuana Enforcement Division; and John Hudak, then a senior fellow at the Brookings Institution. The framework they helped produce was heavily modeled on Colorado's system - mandatory METRC seed-to-sale tracking, mandatory batch testing across seven analyte categories, and a compliance architecture that has since become the default template for adult-use states.
During the period Koski was contracted with Maine, he took a position at METRC - the dominant seed-to-sale tracking company in the United States, whose parent company is Franwell, Inc. - and now serves as its Chief Strategy Officer. Maine's original six-year METRC contract was valued at $540,000. After John Hudak was appointed OCP director in late 2022, the state signed an expanded METRC contract valued at $890,000. Hudak had co-founded a consulting venture with Koski prior to that appointment.
None of this, taken individually, proves a policy decision was improperly made. But in a regulated industry where trust between the state and small operators is the foundation of compliance, the appearance of a revolving door between the architects of METRC-dependent rules and the office now proposing to extend those rules carries real weight. The cannabis community noticed - and responded.
Advocates pushed through LD 1242, a bill that stripped the executive branch's ability to impose new rules on the medical program without originating legislation through the full legislature, with public hearings and elected accountability. That procedural guardrail held for years. It is now, by most accounts, under sustained pressure.
What METRC Compliance Actually Costs Small Operators
The business case against mandatory METRC for medical caregivers is not ideological. It's arithmetic.
Adult-use licensees in Maine currently absorb $40 per month in base METRC fees, RFID tag costs of $0.25 per package and $0.45 per plant, third-party integration software ranging from roughly $100 to $500 per month depending on point-of-sale compatibility, and the less visible but very real costs of compliance labor and system downtime. For a licensed dispensary doing several million dollars annually, those costs are a line item. For a caregiver operating at $250,000 or less in total turnover - which describes the majority of Maine's medical market - they are structurally destabilizing.
That is not an accidental outcome. Compliance cost asymmetry is one of the primary mechanisms through which regulatory frameworks consolidate markets - pricing out small operators, reducing the number of participants, and concentrating supply among better-capitalized entities. Barnett calls METRC "the Voldemort of the cannabis industry," noting that no other agricultural sector faces anything comparable. "True craft businesses, true micro businesses, all the things that folks like to point out as what we should be supporting - Maine is already doing it and has been doing it since '99."
The irony is hard to miss. States and municipalities routinely invoke social equity, small-business access, and craft cultivation as policy goals. Maine's medical program actually delivers those outcomes - not as aspiration, but as demonstrated market structure. Imposing the compliance cost stack that defines adult-use licensing onto that program would not improve it. It would dismantle it, one small caregiver at a time.
What the Market Has Already Decided
The strongest argument for leaving Maine's medical program alone may be the one the market keeps making on its own. In 2021, medical cannabis generated $371 million in sales versus $81 million for adult-use. By 2023, medical had declined to $280 million while adult-use reached $217 million - but medical still led. In a state where patients have full access to both markets, they keep choosing caregivers. OCP Director Hudak himself acknowledged surprise at that pattern, having expected, as most observers did, that adult-use would absorb medical demand by now, as has occurred in other states.
What Maine's numbers suggest is that patients are not choosing the caregiver market because it's the only option. They're choosing it because they trust it. They know the grower's name. They know the farm's practices. In some cases, they know the specific outdoor plot. That relationship - between a registered patient and a small cultivator operating under auditable paper records - is not a regulatory loophole. It is the product.
Barnett frames the stakes without much hedging: the program is not broken, the compliance burden being proposed is not calibrated to fix anything specific, and the people advocating for it have professional histories that connect, one way or another, to the system they want to impose. Whether that adds up to captured regulation or simply to consultants who believe in what they built - that is a judgment Maine's legislature, its patients, and its caregivers are now being asked to make.
For the small operators and licensed businesses watching from other states, the Maine situation is a case study worth following closely. The question it poses is direct: when compliance infrastructure serves the state's fiscal and administrative interests more clearly than it serves the patients and small businesses it ostensibly protects, who is it actually for?
